Second-Generation ALK TKI
FDA approved for the treatment of adult patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK TKI.1
NCCN Category 1, Preferred for 1L.2
Ensartinib is recommended by NCCN as a first-line treatment option for ALK+ metastatic NSCLC (Category 1, Preferred).*
*When an ALK rearrangement is discovered prior to first-line systemic therapy. The NCCN Guidelines for NSCLC provide recommendations for certain individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories. See NCCN reference here.
Ensacove™ is approved for use and available through specialty pharmacies and distributors across the U.S.
Ensacove is a second generation ALK inhibitor that blocks ALK-mediated signaling pathways and inhibits proliferation in cell lines harboring ALK fusions and mutations.1
Efficacy and Safety Demonstrated in eXalt3.1,3
A global, phase III, open-label, randomized, active-controlled, multicenter study.3
Proven Efficacy
Doubles mPFS with 44% reduction in risk of progression or death vs. crizotinib.1,3
Access & Support
Access forms to help patients receive the Ensacove treatment they need.
FDA, Food and Drug Administration; NSCLC, non-small cell lung cancer; ALK, anaplastic lymphoma kinase; TKI, tyrosine kinase inhibitor; NCCN, National Comprehensive Cancer Network; 1L, first‑line; mPFS, modified progression-free survival.